<DOC>
	<DOCNO>NCT00733980</DOCNO>
	<brief_summary>This six-week study evaluate efficacy , safety tolerability GSK561679 compare placebo female subject major depressive disorder</brief_summary>
	<brief_title>A Study Effects New Antidepressant Treatment ( GSK561679 ) Females With Major Depressive Disorder</brief_title>
	<detailed_description>This double-blind placebo control study ass CRF1 receptor antagonist , GSK561679 , treatment depression adult female diagnose Major Depressive Disorder ( MDD ) . A treatment regimen 350mg/day utilized ass efficacy tolerability . Subjects randomize equal number ( n=75/arm ) treatment arm placebo arm 6-week treatment period . Efficacy assess determine change baseline symptom MDD anxiety utilize Bech Melancholia scale ( Bech ) , Hamilton Rating Scale Depression ( HamD17 ) , Inventory Depressive Symptomatology-Self-Report ( IDS-SR ) , Clinical Global Impression - Severity Illness ( CGI-S ) , Clinical Global Impression - Global Improvement ( CGI-I ) , Medical Outcomes Study 12-item Sleep Module ( MOS 12 ) , Cohen Perceived Stress Test ( PSS ) , Hamilton Anxiety Scale ( HamA ) , Dexamethasone Suppression Test ( DST ) . Safety tolerability assess determine incidence adverse event ( AEs ) , vital sign , BMI , weight , clinical laboratory parameter , include ECGs , treatment pre &amp; post-treatment phase , Discontinuation Emergent Signs Symptoms ( DESS ) . In addition , incidence suicidality assess Columbia Suicide Severity Rating Scale ( C-SSRS ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Inclusion criterion : Female outpatient age 2564 year , inclusive . Subjects must ability comprehend consent form , provide informed consent . Subject currently meet diagnosis MDD ( without psychotic feature ) , single episode recurrent , define DSMIVTR , diagnose SCIDCT ( Structural Clinical Interview DSMIV Axis I disorder Clinical Trials Version ) assess * physician adequate training psychiatry ( e.g. , Board Certification psychiatry US equivalent local qualification country ) Subject must , investigator 's opinion base clinical history , meet DSM IVTR criterion current major depressive episode least 4 week great 24 month . Subject IVRS HamD17 total score ≥ 23 Screening Randomization Visits HAMD17 score confirm least 20 Independent Efficacy Rater Screening Randomization Visits . The subject eligible enter participate study lactating : Is nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal [ define one year without menses ] ) ; surgically sterile [ via hysterectomy and/or removal ovary ] , childbearing potential , negative pregnancy test screen baseline ( prior investigational product administration ) , agree acceptable method contraception . Exclusion Criteria Symptoms present illness well account another diagnosis* ; A current DSMIVTR Axis I diagnosis Dementia ; Antisocial Borderline Personality Disorder current DSMIVTR Axis II diagnosis would suggest unresponsiveness pharmacotherapy noncompliance protocol ; A current ( within 12 month prior Screening visit ) diagnosis anorexia nervosa bulimia ; A lifetime history Schizophrenia , Schizoaffective Disorder , Bipolar Disorder . Subject unstable medical disorder disorder would interfere action , absorption , distribution , metabolism , excretion GSK561679 may pose safety concern , interfere accurate assessment safety efficacy . Subject initiated psychotherapy within one month prior Screening visit , plan initiate psychotherapy trial . Subjects present current MDD diagnosis despite longerterm psychotherapy ( i.e. , great three month prior Screening visit ) agree maintain therapy schedule trial may include . Subject receive vagus nerve stimulation , electroconvulsive therapy , transcranial magnetic stimulation within six month prior Screening visit . Subject previously fail adequate therapeutic course pharmacotherapy MDD ( e.g. , maximumlabeled/tolerated dos ≥ 4 week ) two different class antidepressant . Subject , , investigator 's judgement , pose homicidal serious suicidal risk , previous suicide attempt ( include abort , interrupted ineffective attempt ) ever homicidal . Subject contact adult daily basis ( i.e. , subject live least one adult subject adult contact daily basis ) . This criterion apply sit Canadian site others local requirementa . Subject positive urine test screen illegal drug use and/or history substance abuse dependence ( alcohol drug define DSMIV TR criterion ) within past 12 month . Subject blood alcohol level ≥ 15mg/dL ( 0.015 % ) Screening Visit . If subject positive blood alcohol positive illegal drug result , subject provisionally excluded test repeat without prior approval GSK medical monitor . NOTE : Subjects must tell avoid consumption alcoholic beverage least eight hour prior Screening Visit . The use alcohol subject participate study recommend . Subject laboratory abnormality investigator 's judgement consider clinically significant could potentially affect subject safety study outcome . Subject systolic blood pressure ( SBP ) &gt; 160mmHg diastolic blood pressure ( DBP ) ≥ 100 mmHg verify repeated measurement Screening Randomization visit . Subject ( ) currently participate another clinical study subject expose investigational noninvestigational drug device ; ( b ) participate clinical study illness unrelated depression/anxiety within precede month ; ( c ) participate clinical study relate depression/anxiety within precede six month . Documented history hepatobiliary disease include history , positive laboratory result hepatitis ( hepatitis B surface antigen and/or hepatitis C antibody ) Screening , and/or clinically significant hepatic enzyme elevation 13.Subjects euthyroid evidence normal TSH ( subject maintain thyroid medication must euthyroid period least six month prior screen visit ) . Subject positive serum Human Chorionic Gonadotropin ( HCG ) pregnancy test screen visit , positive urine dipstick test randomization , lactate plan become pregnant within next 13 week follow Screen Visit . Subject clinical evidence , ECG result indicate follow either screen Randomization Visit unless repeat ECG show parameter return within normal range Randomisation Visit . ( The ECG may repeat see parameter return within range ) : QTc &gt; 450 msec ; cardiac condition ECG evidence investigator feel may predispose subject ischemia arrhythmia ; ECG abnormality , investigator 's judgment , may pose potential safety concern . Subject take psychoactive drug within one week prior ScreeningScreening Randomization Visit Subject take systemic corticosteroid acutely within two week chronically within last 6 month Randomization Visit ( NOTE : Topical hydrocortisone inhale corticosteroid allow ) . Subject take ( nonpsychoactive ) prescription , nonprescription , dietary , herbal product metabolize via cytochrome P450 3A4 pathway , Pgp substrates narrow therapeutic index within 2 week ( 5 halflives , whichever long ) prior Randomization Visit . Subject take ( nonpsychoactive ) prescription , nonprescription , dietary , herbal product potent inducer inhibitor cytochrome P450 3A4 pathway 2 week ( 5 half life , whichever long ) prior Randomization Visit . Subject previously participate investigational trial involve GSK561679 closely related compound . Subject history allergic reaction , significant adverse effect excipients GSK561679 tablet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
</DOC>